"Politics has won out over science -- and doctors, scientists, and humanitarians are right to feel abhorrence that a new human tragedy has been imposed on Crimea," Michel Kazatchkine said in a commentary published by the British Medical Journal (BMJ).
Kazatchkine said that under Ukrainian rule, Crimea provided addicts with access to methadone, a safer substitute for heroin, and to buprenorphine, a drug used to ease dependence.
Endorsed by the World Health Organisation (WHO), this "substitution" therapy is a proven success in weaning addicts off heroin and halting the spread of HIV, Kazatchkine said.
"This will bring unnecessary suffering to the people of Crimea and is a blatant example of health policy being hijacked for political ends rather than being led by evidence," he charged.
Dosages of drugs for the 800 people enrolled in Crimea's substitution programme were gradually reduced from mid-March and the therapy officially stopped on May 1, Kazatchkine said.
About 80 people have sought to leave Crimea to continue treatment, 32 of whom are also receiving AIDS drugs, he said, quoting the International HIV/AIDS Alliance in Ukraine.
"Many of these services are limited, however, if available at all in Russia," said Kazatchkine.
Kazatchkine, a former chief of the Global Fund to Fight AIDS, Tuberculosis and Malaria, published his comments ahead of a conference in Moscow on the HIV/AIDS epidemic in eastern Europe and central Asia next Monday and Tuesday.
Russia has one of the fast-growing tallies for HIV infections in the world. Experts say the spread is being driven by intravenous drug use, but is now entering the mainstream community.
Russia accounts for over 55 per cent of all new HIV infections reported in the European region, according to the European Centre for Disease Prevention and Control (ECDC).
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
